Esperovax Announces U.S. Patent Allowance for In Vivo Therapeutic Protein Expression Platform
Esperovax Announces U.S. Patent Allowance for In Vivo Therapeutic Protein Expression Platform
PR Newswire
PLYMOUTH, Mich., Sept. 11, 2026
PLYMOUTH, Mich., Sept. 11, 2026 /PRNewswire/ -- Esperovax, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/038,673, entitled "Yeast-Based Expression of Therapeutic Proteins In Vivo."
The allowed patent application covers technology developed by Esperovax for using engineered yeast as a platform for the in vivo production of therapeutic proteins. The approach is designed to enable therapeutic proteins to be produced directly within the body following administration of engineered yeast, creating opportunities for localized, sustained, and potentially more accessible delivery of biologic medicines.
The allowance represents an important expansion of Esperovax's intellectual property portfolio and provides protection for a technology platform with potential applications across multiple therapeutic areas.
"This patent allowance validates an important part of the scientific foundation we have built at Esperovax," said David O'Hagan, Ph.D., CEO of Esperovax. "Rather than manufacturing every therapeutic protein externally and repeatedly administering the purified biologic, our technology creates the possibility of programming yeast to function as an in vivo therapeutic protein production system. We believe this approach could ultimately enable new ways of delivering biologic medicines."
The technology is particularly compelling for applications in which localized or sustained expression of therapeutic proteins could provide advantages over conventional systemic protein administration.
Following completion of the USPTO's issuance requirements, the application is expected to proceed to issuance as a U.S. patent.
About Esperovax
Esperovax, Inc. is a biotechnology company developing innovative nucleic-acid and biologic technologies designed to enable new approaches to the prevention and treatment of disease. The company's intellectual property portfolio includes platforms for engineered biological delivery and therapeutic protein expression.
U.S. Patent Application No. 18/038,673 — "Yeast-Based Expression of Therapeutic Proteins In Vivo."
SOURCE Esperovax
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
3 Stocks to Sell and 3 Stocks to Buy for October
The Top Funds for a Simpler Retirement Portfolio
United States